Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Damylin + codeine is a combination oral syrup medication containing **codeine phosphate**, **diphenhydramine hydrochloride**, and **ammonium chloride**. It is indicated for the relief of cough and nasal congestion. **Codeine phosphate** is an opioid analgesic and cough suppressant primarily acting as a prodrug metabolized to morphine, which exerts central effects via opioid receptors. **Diphenhydramine hydrochloride** is a first-generation antihistamine with anticholinergic and sedative effects, acting as an antagonist of the histamine H1 receptor. **Ammonium chloride** acts as an expectorant, facilitating the clearance of mucus from the respiratory tract. This product is marketed for symptomatic relief and is classified as a narcotic under regulatory schedules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on damylin + codeine.